NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Uncommon Therapeutics

Uncommon Therapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.uncommontherapeutics.com/

Last Round

Seed

Feb 1, 2025

Total Funding Raised

$500,000

Company Overview

Uncommon Therapeutics is a biotechnology company that develops gene-based and multi-modal therapeutics for rare neurodevelopmental monogenic diseases, with an initial focus on Rett Syndrome.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

rare disease therapeuticspolytherapyRett Syndromegene editingASOantisense oligonucleotidesdrug discoverybiotech startupAI-driven drug discoverysmall molecule therapyneurodevelopmental disordersmonogenetic diseaseprecision medicinedrug licensingbiotech platformin silico drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Uncommon Therapeutics Comparables

Compare Uncommon Therapeutics with similar companies based on industry and business-model similarity.

Uncommon Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Unravel Biosciences
76%
Neurogene
74%
Taysha Gene Therapies
70%

Uncommon Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 1, 2025

Key People

Founding team and executive leadership

Noah Auerhahn

Founder & CEO

Founding Team

Uncommon Therapeutics Investors

Notable investors and investment history

Uncommon Therapeutics investors
InvestorRounds
Pioneer FundSeed
Ethos FundSeed
Singularity CapitalSeed
Y CombinatorSeed
Roar VenturesSeed
Angel Operator PartnersSeed

Uncommon Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Uncommon Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Uncommon Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range4
Year Founded2024
Last FundingFeb 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.